32. Claesson MH. Veto cell H-2 antigens: veto cell activity is restricted by determinants encoded by K, D, and I MHC regions. Cell Immunol. 1987; 109:360-370.
33. Sambhara SR, Miller RG. Programmed cell death of T cells signaled by the T cell receptor and the alpha 3 domain of class I MHC. Science. 1991; 252:1424-1427.
34. Sambhara SR, Miller RG. Reduction of CTL anti-peptide response mediated by $CD8^+$ cells whose class I MHC can bind the peptide. J Immunol. 1994;152:1103-1109.
35. Hiruma K, Nakamura H, Henkart PA, Gress RE. Clonal deletion of postthymic T cells: veto cells kill precursor cytotoxic T lymphocytes. J Exp Med. 1992;175:863-868.
36. Reich-Zeliger S, Zhao Y, Krauthgamer R, Bachar-Lustig E, Reisner Y. Anti-third party $CD8^+$ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity. 2000;13:507-515.
37. Bachar-Lustig E, Reich-Zeliger S, Reismen Y. Synergism between rapamycin and host-non-reactive veto CTLs in murine models for BM allograft rejection: a new approach to facilitate engraftment of T cell depleted allogeneic BMT under reduced intensity conditioning. Blood. 2002;100:211a.
38. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol. 1998;160:5355-5365.
39. Taylor P, Lees C, Wilson J, et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood. 2002;100:3400-3407.
40. Sha WC, Nelson CA, Newberry RD, Kranz DM, Russell JH, Loh DY. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature. 1988;335:271-274.
41. Fowler DH, Whitfield B, Livingston M, Chrobak P, Gress RE. Non-host-reactive donor CD8(+) T cells of Tc2 phenotype potently inhibit marrow graft rejection. Blood. 1998;91:4045-4050.
42. Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE. Allospecific $CD8^+$ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol. 1996;157:4811-4821.
43. Mutis T, Blokland E, Kester M, Schrama E, Goulmy E. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood. 2002;100:547-552.
44. Mutis T, Goulmy E. Targeting alloreactive T cells to hematopoietic system specific minor histocompatibility antigens for cellular immunotherapy of hematological malignancies after stem cell transplantation. Ann Hematol. 2002;81(suppl 2):S38-S39.
45. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A. 2003;100:2742-2747.
46. Nair SK, Heiser A, Boczkowski D, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med. 2000;6:1011-1017.
47. Molldrem JJ, Kant S, Jiang W, Lu S. The basis of T-cell-mediated immunity to chronic myelogenous leukemia. Oncogene. 2002;21:8668-8673.
48. Guillet M, Sebille F, Soulillou J. TCR usage in naive and committed alloreactive cells: implications for the understanding of TCR biases in transplantation. Curr Opin Immunol. 2001;13:566-571.

Erratum

In the article by Blaha et al entitled “The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade,” which appeared in the April 1, 2003 issue of *Blood* (Volume 101:2886-2893), Figure 4’s panel C is incorrect. The correct panel C appears below: